Resources

News

#{post.title}

#{post.description}

Read

Read more news

Events

Targeted Radiopharmaceuticals Summit

July 30-August 1, 2024 - San Diego

ESMO 2024

September 13-17, 2024

EANM 2024

October 19-23, 2024

Scientific Publications

Targeted Alpha-Emitter Therapy with 212Pb-DOTAMTATE in Neuroendocrine Tumor Subjects who Progressed Following Prior 177Lu/90Y-PRRT, Poster presented at ASCO 2022

Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003

VCAM-1 targeted alpha-particle therapy for early brain metastases

212Pb Alpha-Radioimmunotherapy targeting CD38 in Multiple Myeloma: a preclinical study

Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy

Safety and Outcome Measures of First-in-Human Intraperitoneal Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

See more scientific publications

By clicking “I accept Cookies”, you agree with the cookies use to enhance site navigation, analyze site usage and compile statistics. To get more information, please read our Cookies Policy in the Legal Notice

I accept cookies I refuse cookies